Effectiveness of an Algorithm-Based Approach to the Utilization of Plerixafor in Patients Undergoing Chemotherapy-Based Stem Cell Mobilization  by Chow, Eric et al.
E. Chow et al. / Biol Blood Marrow Transplant 20 (2014) 1056e10731064Effectiveness of an Algorithm-Based
Approach to the Utilization of Plerixafor in
Patients Undergoing Chemotherapy-Based
Stem Cell Mobilization
Eric Chow*, Kamakshi V. Rao, William A. Wood,
Deborah Covington, Paul M. Armistead, James Coghill,
Jonathan S. Serody, Don A. Gabriel, Katarzyna J. Jamieson,
Yara A. Park, Jay S. Raval, Thomas C. Shea
Department of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NCArticle history:
Received 31 December 2013
Accepted 19 March 2014
Key Words:
Stem cell mobilization
Etoposide
Plerixafor
Autologous stem cell
transplantationFinancial disclosure: See Acknowl
* Correspondence and reprint re
of Pharmacy, University of No
101 Manning Drive, CB #7600, Cha
E-mail address: echow1@u.was
1083-8791/$ e see front matter 
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Autologous stem cell transplantation remains a mainstay of therapy for diseases such as multiple myeloma
and relapsed lymphoma. The use of plerixafor has been shown to augment the ability to collect adequate
stem cells, but the optimal use of this agent when used with chemotherapy is not yet clear. We utilized an
algorithm-based approach with the addition of plerixafor to 54 patients undergoing chemomobilization with
reduced-dose etoposide who had a less than optimal preapheresis CD34þ cell count. We used a CD34þ
precount of 20 cells/mL as a threshold to initiate stem cell apheresis. Ninety-four percent of patients were
successfully collected and proceeded to transplantation. Fourteen of 51 (28%) patients who successfully
collected required plerixafor to augment stem cell yield. Of the patients who successfully collected, 94% (89%
of the entire population) were able to collect in 2 or fewer days. Compared with previous data from our
institution, the rate of patients collecting > 4  106 CD34þ cells/kg in a single collection was increased from
39% to 69%. The safety proﬁle of this approach was acceptable. The use of this algorithm-based method to
determine when and whether to add plerixafor to chemomobilization was shown to be a successful and cost-
effective approach to stem cell collection.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous stem
cell transplant (ASCT) remains an essential treatment mo-
dality in efforts to achieve a durable complete remission for
patients with non-Hodgkin’s lymphoma (NHL), Hodgkin’s
disease, and multiple myeloma (MM) [1,2]. The mobilization
and adequate collection of hematopoietic stem cells (HSCs)
by apheresis is necessary for allowing patients to undergo
this procedure. Strategies for HSC mobilization include the
administration of granulocyte colonyestimulating factors
(GCSF), with or without chemotherapy, to stimulate the
production of these cells. Unfortunately, factors such as age>
65 years, advanced disease with bone marrow involvement,
and exposure to radiation and/or HSC-toxic agents can lead
to poor mobilization or mobilization failure. Published data
has reported a range for mobilization failure between 5% and
30% of patients [3,4]. As a result, current research regarding
HSC mobilization has continued to focus on optimizing the
efﬁciency of apheresis collection in an effort to reduce cost
and minimize the number of procedures required to collect
sufﬁcient cells [5].edgments on page 1067.
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14.03.023For single transplantations, the collection of at least
2  106 CD34þ cells/kg is accepted as the minimal yield to
proceed with transplantation, although for patients with
MM, consensus guidelines have recommended a collection
yield of at least 4  106 CD34þ cells/kg in preparation for
potential tandem transplantation [6]. Plerixafor is a novel
agent that interferes with the interaction between stromal
derived factor-1 and the CXCR4 receptor. Disruption of this
interaction causes a rapid release of HSCs from the bone
marrow into peripheral circulation [7]. For patients with MM
and lymphoma who have difﬁculty achieving the required
minimum yields for transplantation, plerixafor combined
with GCSF has been shown to signiﬁcantly increase CD34þ
collection yields [8-12]. Given the cost of plerixafor, limited
apheresis availability, and cost of HSC product storage, recent
studies have focused on determining the appropriate use of
plerixafor in combination with GCSF to optimize mobiliza-
tion and collection.
Abhyankar et al. described a risk-based algorithm that
used peripheral CD34þ screening to help guide the admin-
istration of plerixafor in addition to ﬁlgrastim in an effort to
optimize collection and decrease resource utilization. Using
this risk-based approach, their patients were able to collect
an adequate number of cells within 2 apheresis sessions and
plerixafor was only needed in 34.5% of patients, with a 2%
failure rate [13].
Chemotherapy-based mobilization is a mobilization
strategy that uses chemotherapy to stimulate the production
of HSCs in the bone marrow and their subsequent release
into the peripheral blood. When combined with GCSF,
Table 1
Patient Characteristics
Characteristic Value
N 54
Male, % 63%
Age, average (range), yr 53.9 (20-74)
Disease
NHL 31
MM 21
Other (APL, germ cell) 2
Characteristics of patients requiring plerixafor
n 15
Disease
NHL 11
MM 4
First pre-CD34þ count
<10 cells/mL 9
10 but < 20 cells/mL 6
Post-plerixafor CD34þ count
<10 cells/mL 3
10 cells/mL 12
APL indicates acute promyelocytic leukemia; NHL, non-Hodgkin’s
lymphoma; MM, multiple myeloma.
Data presented are n, unless otherwise indicated.
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mobilization have been shown to be signiﬁcantly higher than
with GCSF alone [14,15]. Additionally, mobilization with
chemotherapy and GCSF has been shown to overcome
known factors that predict difﬁcult mobilization in MM and
NHL such as advanced age, prior thalidomide/lenalidomide,
radiation exposure, or heavy pretreatment [6,16].
Despite the improvement in HSC yield seen with
chemotherapy-basedmobilization, there remain a number of
patients who either fail tomobilize, have lower HSC yields, or
require multiple days and large collection volumes of
apheresis collections to obtain adequate HSC yields. Previous
data fromour institution has demonstrated thatmobilization
with etoposide and GCSF results in an overall successful
collection rate of 100% in MM patients and 94% in lymphoma
patients. Ninety-nine percent of MM patients and 57% of
lymphoma patients were classiﬁed as “good mobilizers,”
deﬁned as those who collected > 5  106 CD34þ cells/kg in 2
or fewer apheresis sessions [5,16]. This CD34 dose is mean-
ingful because it has been shown that infusion of > 5  106
CD34 cells/kg is associated with signiﬁcantly faster neutro-
phil and platelet recovery in ASCT patients compared to
doses of 2 to 5  106 cells/kg [17-21]. Although good mobi-
lizers collected > 5  106 cells/kg in  2 days, patients whoFigure 1. Chemomobilidid not meet this deﬁnition, ie, “poor mobilizers,” required
double the number of apheresis sessions (ie, 4), with 27% not
achieving the goal of 5  106 cells/kg.
The optimal use of plerixafor combined with chemo-
therapy and GCSF has not been well described in the
literature. Recent studies involving plerixafor combined
with chemotherapy and GCSF have shown signiﬁcant in-
creases in HSC yields and reductions in apheresis utiliza-
tion [22-24]. However, questions remain on whether every
patient undergoing chemomobilization requires plerixafor
or if there are strategies that can be employed to selec-
tively administer plerixafor to patients at high-risk of
failing chemomobilization.
The use of peripheral WBC and CD34þ cell counts to
predict successful GCSF mobilization and apheresis collec-
tion has been demonstrated at other institutions [13,25]. We
used these 2 factors to develop an algorithm that in-
corporates chemotherapy with predetermined decision
points to help guide the administration of plerixafor and
when to proceed with HSC collection. The purpose of this
analysis was to evaluate the safety and efﬁcacy of this
etoposide-based chemomobilization algorithm with pre-
determined decision points for plerixafor administration to
selectively use plerixafor for high-risk patients, augment HSC
collection yields, and reduce apheresis utilization.
MATERIALS AND METHODS
Study Patients
Institutional review board approval from the University of North Car-
olina at Chapel Hill was obtained for the purpose of this analysis. Between
May 2012 and May 2013, patients with lymphoma and MMwho were likely
to be difﬁcult mobilizers received etoposide and GCSF with or without
plerixafor according to institutional guidelines. Difﬁcult mobilizers were
deﬁned as any patient with lymphoma, MM patients who had received
greater than 6 cycles of a lenalidomide-containing regimen, patients un-
dergoing predetermined tandem transplantations, or patients who had
previously failed GCSF mobilization. Overall patient characteristics are
illustrated in Table 1.
Mobilization and PBSC Collection Regimen
A chemomobilization algorithm was developed combining circulating
WBCs and peripheral CD34þ cell counts after at least 10 days of GCSF to
guide decisions on CD34þ cell collection and the administration of plerixafor
(Figure 1). HSCs were mobilized with etoposide at a dose of 300 mg/m2
diluted to a concentration of .4 mg/mL and infused over 4 hours for 2
consecutive days. Patients received ondansetron, 24 mg daily, and dexa-
methasone, 20 mg orally, before each etoposide infusion, as well as pro-
chlorperazine, 10 mg every 4 hours as needed, for nausea or emesis.
Antimicrobial prophylaxis was given concurrently using levoﬂoxacin
500 mg orally once daily to all patients beginning on day 5. GCSF was
administered at a dose of 10 mg/kg/day beginning on day 3 and continuedzation algorithm.
Table 2
Results of Successful Collections
Overall N ¼ 51 Plerixafor No Plerixafor
n 14* 37
Age, mean (range), yr 59 (37-66) 51 (20-74)
Disease
NHL 9 19
MM 5 16
Other 0 2
CD34þ cell collection, median,
 106 cells/kg
4.30 5.99
No. of collections, median (range) 2 (1-4) 1 (1-2)
No. of plerixafor doses, median (range) 2 (1-4) -
Days of collection required (%)
1 6 (43) 29 (78)
2 5 (36) 8 (22)
3 2 (14) -
4 1 (7) -
Good mobilizers, n (%)y 9 (64) 31 (84)
Patients hospitalized, n (%) 4 (29) 4 (11)
NHL indicates non-Hodgkin’s lymphoma; MM, multiple myeloma.
* Mobilization was aborted for 1 patient after having persistently low
CD34þ counts (<10 cells/mL) after 2 doses of plerixafor; thus, this patient
was not included in the analysis above.
y Deﬁned as collecting > 4  106 cells/kg within 2 apheresis sessions.
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had been collected.
Beginning on day 12 after chemotherapy administration, evaluation of
each patient’s WBC and CD34þ cell count determined whether they would
proceed to apheresis collection, continue ﬁlgrastim, or receive plerixafor in
addition to ﬁlgrastim. A CD34þ count of 20 CD34þ cells/mL was used as the
initial determinant for proceeding to apheresis collection. Patients whose
initial CD34þ count was  20 cells/mL received plerixafor, and if their sub-
sequent CD34þ count was > 10 CD34þ cells/mL, apheresis collection with
daily plerixafor support was attempted to maximize the potential for
obtaining a transplantable dose of HSCs. Target volumes of collection were
calculated based on an algorithm that includes the patient’s weight in ki-
lograms, the peripheral precollection CD34þ count, and the requested HSC
dose. The algorithm predicts the number of liters of patient’s blood that
must be processed. If the algorithm predicts a collection volume that ex-
ceeds 6 times the patient’s total blood volume, the collection is ended after
6 hours and, if the dose is not achieved, a second day of collection occurs.
Patients unable to collect the minimum 2  106 CD34þ cells/kg yield in
3 days of collection or those who fail to adequately respond (peripheral
blood count < 10 CD34þ cells/mL) after 1 dose of plerixafor were considered
mobilization failures. All collections were performed using the COBE Spectra
Apheresis System (TerumoBCT, Lakewood, CO). The complete decision tree is
shown in Figure 1.
Study Objectives
The goals of this analysis were to (1) establish the safety and efﬁcacy of
chemomobilization with a reduced dose of etoposide with regards to
mobilization yield, apheresis time, and incidence of adverse effects, and (2)
assess the effectiveness of an algorithm-based approach to the use of pler-
ixafor to augment stem cell collection yields in patients who are at high risk
of failed mobilization while optimizing resource utilization.
Safety
Safety endpoints with regards to rate of febrile neutropenia and hos-
pitalizations of any kind were assessed for all available patients. Data for
safety was obtained retrospectively from electronic medical records.
Statistical Analysis
Descriptive statistics were used in this analysis.
RESULTS
Efﬁcacy
Between May 2012 and May 2013, a total of 54 patients
attempted PBSC mobilization with etoposide in preparation
for ASCT at the University of North Carolina Hospitals and
Clinics. Of the 54 patients, 51 (94%) were collected success-
fully with an HSC yield greater than 2  106 CD34þ cells/kg.
Forty-eight of these 51 patients (94%) collected in 2 or fewer
apheresis sessions. In our NHL population, all of the patients
(n ¼ 19) who did not require plerixafor and 7 of the 10
patients who did require plerixafor were able to collect the
minimum yield of 2  106 CD34þ cells/kg in 2 apheresis
sessions or fewer. Plerixafor was required in 15 (28%)
patients, whereas 37 (69%) were able to collect adequate
HSCs without plerixafor support. Comparing those requiring
plerixafor with those who did not, patients not requiring
plerixafor collected a higher median CD34þ cell yield
(5.99  106 cells/kg versus 4.30  106 cells/kg); did not
require plerixafor support during collection, indicating that
all patients were able to collect > 50% of goal after the ﬁrst
apheresis session; and required fewer median apheresis
sessions (1 session versus 2 sessions). The majority of pler-
ixafor patients were still able to successfully collect within 2
apheresis sessions, with only 11 requiring 1 to 2 plerixafor
doses. Patients requiring plerixafor were more likely to carry
an underlying diagnosis of lymphoma and were older than
patients who collected successfully without plerixafor. All
patients who successfully collected have proceeded to
transplantation.
Three of the 54 patients failed to collect adequate HSCs.
Two of the 3 were heavily pretreated NHL patients, one ofwhom received 2 doses of plerixafor and still failed to
mobilize because of persistently low CD34þ cell counts
(<10 cells/mL) after each plerixafor administration. After
consultation between the providers and the pharmacist, the
patient proceeded with a bone marrow harvest in lieu of
remobilization. The other patient with mobilization failure
had an undetectable preapheresis CD34þ cell count at day 14
after chemotherapy, so plerixafor was not administered and
the patient proceeded to bone marrow harvest, as well. The
last individual who failed mobilization was a MM patient
who was hospitalized and expired before a preapheresis
CD34þ count was checked. Thus, 14 of 15 patients who
received plerixafor had successful stem cell collections and
were able to proceed to ASCT. Full results are available in
Table 2.Safety
Of the 54 patients who received etoposide mobilization, 8
patients (15%) were hospitalized for neutropenic fever. One
of these 8 patients was a 69-year old heavily pretreated MM
patient who was hospitalized for febrile neutropenia, sub-
sequently suffered a myocardial infarction during hospitali-
zation, and expired before a peripheral CD34þ assessment
was performed. This patient had underlying cardiovascular
comorbidities, which likely increased his/her risk for car-
diovascular events.DISCUSSION
For patients who have risk factors for difﬁcult mobiliza-
tion of PBSC, chemotherapy combined with GCSF and pler-
ixafor is effective in successfully mobilizing HSCs in
preparation for ASCT. Previous data from our institution us-
ing etoposide mobilization at a dose of 375 mg/m2 for 2
consecutive days in our heavily pretreated MM and lym-
phoma patients demonstrated that 99% of MM and 57% of
lymphoma patients were good mobilizers, deﬁned as the
ability to collect at least 5  106 cells/kg in 1 to 2 days [5,16].
In our current experience, we show that in a mixed popu-
lation of heavily pretreated MM and NHL/Hodgkin disease
patients, we were able to use a reduced dose of etoposide
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maintain both the overall rate of successful mobilizations
along with a high rate of good mobilization. The efﬁciency of
collectionwith this approach was better thanwith etoposide
alone at a higher dose, as 48 of 51 successful collectors
collected in 2 or fewer apheresis sessions, compared with a
median of 4 apheresis sessions in poor mobilizers with our
previous experience [5,16]. Of note, the approach resulted in
69% of patients being able to collect > 4  106 cells/kg in a
single collection day. This is a marked improvement from our
prior experience, where without the use of this algorithm,
only 39% of patients collected > 4  106 cells/kg in a single
collection.
When we analyzed resource utilization in patients
requiring plerixafor, our current experience demonstrated
that the majority of patients were still able to successfully
collect within 2 apheresis sessions, albeit with lower
collection yields. Only 2 of the 15 patients requiring plerix-
afor met the criteria for good mobilization, as deﬁned in our
previous publication as the ability to collect  5  106 cells/
kg within 2 apheresis sessions. However, it is important to
note that current standard practice at our institution is to
collect a goal of 4 106 cells/kg. With the modiﬁcation of our
deﬁnition of good mobilization to reﬂect this new collection
goal, 9 of the 15 patients (60%) who were given plerixafor
now met criteria for good mobilization. In our approach, we
used a preapheresis CD34þ cell count of 20 CD34þ cells/mL as
a threshold for initiating apheresis collection. The success
rate and the efﬁciency of apheresis reported here afﬁrms that
this threshold adequately predicts successful collection,
while limiting the use of plerixafor to only those who require
it, as well as reduces the number of apheresis procedures
required for adequate collection, compared with our previ-
ous experience. Although a formal cost analysis was not
done, we previously performed a break-even analysis that
compared the cost of mobilization with the reference cohort
with the estimated cost of mobilization when a median of 2
doses of plerixafor was administered to predicted poor
mobilizers. In that break-even analysis, the authors
concluded that 49% of predicted poor mobilizers who
received a median of 2 doses of plerixafor would have to
convert from poor to good mobilization to achieve cost
neutrality. In our present analysis, we were able to demon-
strate that of the 15 patients who required a median of 2
doses of plerixafor and would have been classiﬁed as poor
mobilizers, 60% were able meet criteria for good mobiliza-
tion, exceeding the 49% required for cost neutrality [5].
The results of our study are consistent with similar
studies utilizing preapheresis collection CD34þ screening for
GCSF mobilization combined with plerixafor support. At the
University of Kansas, the implementation of their risk-based
algorithm for GSCF mobilization resulted in only 35% of their
patients receiving plerixafor along with a signiﬁcant reduc-
tion in patients who required remobilization [13]. In our
study using chemomobilization, we were also able to
demonstrate selective use of plerixafor in patients under-
going chemomobilization with etoposide with a high rate of
success and limited its use to 28% of our high-risk population.
With regards to safety, our use of etoposide at a dose of
300 mg/m2 over 2 consecutive days resulted in 8 patients
(15%) requiring hospitalizations, with the most frequent
diagnosis being neutropenic fever, despite all patients
receiving antimicrobial prophylaxis during the mobilization
process. This rate did not differ signiﬁcantly from our pre-
vious experience in a mixed population of 311 patients,which resulted in 32 patients (10%) requiring hospitalization
for neutropenic fever, with an additional 4 patients receiv-
ing outpatient intravenous antibiotics. In studies using
cyclophosphamide at doses ranging from 1.2 g/m2 to 7 g/m2,
the incidence of neutropenic fever ranged from 15% to 72%
[14,15,21]. Although our rate of hospitalization and incidence
of neutropenic fever compares favorably with historical data
utilizing chemotherapy-basedmobilization, it also highlights
the inherent risk associated with this modality of
mobilization.
In summary, we were able to demonstrate a high rate of
successful HSC collection with low resource utilization and
adequate safety through the application of a chemo-
mobilization algorithm that included reduced-dose etopo-
side and GCSF combined with predetermined decision points
for plerixafor support and collection.ACKNOWLEDGMENTS
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Childrena b s t r a c t
Data on epidemiology of severe infectious complications, ie, bacteremia or invasive fungal disease (IFD), in
children with acute graft-versus-host disease (aGVHD) after allogeneic hemopoietic stem cell transplantation
(HSCT) are scarce. In a retrospective, single-center study, we analyzed the risk (hazard ratio [HR]) and the rate
(episodes/1000 patients days at risk) of bacteremias and IFD in children receiving allogeneic HSCT, according
to the type of donor (matched related [MRD] or alternative [AD]) and presence and grade of aGVHD. From
2000 to 2009, 198 children receiving 217 allogeneic HSCT developed 134 severe infectious episodes
(103 bacteremias and 31 IFD). The type of donor (AD versus MRD) was the most important risk factor for the
severe infections (P ¼ .0052). In separate multivariable analysis for bacteremia and IFD, children receiving an
AD HSCT had increased HR and rate of bacteremia compared with those receiving a MRD transplantation
(P ¼ .0171 and P ¼ .0001, respectively), whereas the HR and the rate of IFD were signiﬁcantly inﬂuenced by the
grade of aGVHD (P ¼ .0002 and P < .0001, respectively). Finally, infectious episodes occurred late after HSCT,
especially in presence of severe aGVHD, and bacteremias were 3 to 6 times more frequent than IFD. These
data may be important to design management strategies of infections in pediatric allogeneic HSCT.
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Bacteremia and invasive fungal diseases (IFD) represent
severe complications for patients receiving allogeneic
hemopoietic stem cell transplantation (HSCT) [1-4]. These
infections are more frequent in subjects receiving HSCT from
an alternative donor (AD) than from a matched related donor
(MRD) [1]. During a prospective survey of adverse events
occurring in patients with steroid-resistant acute graft-
versus-host disease (aGVHD), we observed that the
